News

The decision to return the rights of tozadenant has been made on the assessment of UCB’s early and late stage clinical development pipeline as well as its preclinical

The European Medicines Agency’s (EMA) CHMP has issued positive opinions for the conditional marketing authorizations of Vynfinit, Folcepri and Neocepri to treat adult patients with folate receptor-positive, platinum-resistant,

This satisfies the necessary patient numbers proposed for the trial. Following from the positive results achieved from the interim analysis of the serum Insulin-like Growth Factor-I (sIGF-I) data

Medivir CEO Maris Hartmanis said: "The recommendation is one additional step in the global strategy that our partner Janssen has for simeprevir, to offer a new and efficacious

According to the recommendation, Bexsero should be routinely used in infants from two months of age to help protect against meningococcal serogroup B (meningitis B). The implementation will

NCCN ORP vice president Dr Diane E. Paul noted it is grateful to collaborate with Boehringer Ingelheim on this ground-breaking research initiative. "The research supported by this grant

The patent (No. 8,663,987) covers BrainStorm’s proprietary stem cells induced to secrete elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases. The neurotrophic factors secreted by

The drug is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who

The results showed that the trial did not meet its first or second co-primary endpoint as it did not significantly extend disease-free survival (DFS) when compared to placebo